Browse the evidence

Tirzepatide achieves unprecedented weight loss, but case reports suggest potential sexual side effects.

Clinicians should monitor for potential sexual side effects in patients using Tirzepatide for weight loss.

There is a risk of excessive reduction in skeletal muscle mass (SMM) with GLP-1-based therapies.

Practitioners should monitor muscle mass in patients using GLP-1 therapies to mitigate risks of sarcopenia.

GLP-1 receptor agonists enhance insulin secretion, support weight loss, and exhibit neuroprotective and cardiovascular benefits.

Practitioners can consider GLP-1 receptor agonists for their multifaceted benefits in diabetes management.

Use of incretin-based therapies (IBT) after bariatric surgery is associated with a 55% lower risk of new-onset alcohol use disorder (AUD) compared to non-IBT antiobesity medications (AOMs).

Practitioners may consider prescribing IBT for patients post-bariatric surgery to reduce the risk of AUD.

IBT is associated with a 41% lower risk of initiation of medications for alcohol use disorder (MAUDs) compared to non-IBT AOMs.

IBT may be a beneficial option for reducing the need for MAUDs in post-bariatric surgery patients.

Non-Hispanic Black (NHB) participants had lower percent total weight loss (%TWL) at 3, 12, and 24 months compared with Hispanic (H) and non-Hispanic White (NHW) participants.

Healthcare providers should consider racial and ethnic differences when evaluating weight loss outcomes post-surgery.

GLP-1RA use was associated with a lower risk of major adverse cardiovascular events (MACE) in nondiabetic patients with PAD (HR: 0.61; 95% CI: 0.57–0.66; p < 0.001).

GLP-1RAs may be beneficial for reducing cardiovascular risks in patients with PAD who do not have diabetes.

Tirzepatide helps lower blood sugar levels in patients with type 2 diabetes mellitus.

Tirzepatide can be considered for managing blood sugar levels in type 2 diabetes.

Metabolic and bariatric surgery (MBS) is the most effective long-term treatment for severe obesity and its associated comorbidities.

MBS should be considered as a primary treatment option for patients with severe obesity.

MBS is associated with improved glycemic and metabolic control, lower apnea burden, reduced risk of major adverse cardiovascular events, and improved overall survival.

MBS can significantly improve health outcomes for patients with severe obesity.

GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 31% in Asians.

GLP-1RAs may provide significant cardiovascular benefits for Asian populations.

Tirzepatide produced meaningful weight loss across groups, but outcomes varied based on weight-reduction status and T2D status.

Practitioners should consider individual patient factors when prescribing tirzepatide for weight loss.

GLP-1/dual agonists were associated with a 54% lower incidence of physician-reported sleep apnea (PRSA).

Practitioners may consider GLP-1/dual agonists as a treatment option to reduce the incidence of sleep apnea in patients with obesity and type 2 diabetes.

Liraglutide, dulaglutide, semaglutide, and tirzepatide individually reduced the incidence of PRSA compared to the reference arm.

Each GLP-1/dual agonist may be effective in reducing sleep apnea incidence, offering multiple treatment options.

There was a 79% lower incidence of positive airway pressure reports in the GLP-1/dual agonist group compared to controls.

The use of GLP-1/dual agonists may lead to fewer patients requiring positive airway pressure therapy.

Glucose-dependent insulinotropic polypeptide (GIP) acts as a bifunctional blood sugar stabilizing factor in type 2 diabetes.

GIP may be considered in therapeutic strategies for managing blood sugar in type 2 diabetes.

The dual stimulation of the GIP and GLP1 receptor may provide benefits in treating type 2 diabetes and obesity.

Consider dual receptor agonists in treatment plans for better outcomes in diabetes and obesity.

The S3 guideline for the prevention and treatment of obesity includes new recommendations on stigmatization, diagnostics, and therapy, incorporating areas like E-Health.

Practitioners should consider the new recommendations in their approach to obesity treatment.

GLP-1 receptor (GLP-1R) agonists significantly reduce the occurrence of major adverse cardiovascular events in individuals with type 2 diabetes (T2D).

Practitioners should consider GLP-1R agonists as a therapeutic option for reducing cardiovascular risks in T2D patients.

Cricket protein ingestion results in higher postprandial blood amino acid concentration compared to beef protein.

Insect protein may be more effective than some traditional animal proteins for amino acid delivery.

There is no difference in skeletal muscle anabolism between insect and animal protein sources.

Both insect and animal proteins can be used interchangeably for muscle building.

Incretin-based glucose-lowering medications, including DPP-4 inhibitors and GLP-1 receptor agonists, open new perspectives in the treatment of type 2 diabetes.

Practitioners should consider incretin-based therapies as viable options for managing type 2 diabetes.

The dual receptor agonist tirzepatide has been approved for clinical use by the FDA.

Healthcare providers can now prescribe tirzepatide as part of diabetes management.

The treatment of obesity is undergoing significant changes due to new weight-reducing medications, innovations in intervention, digital therapy options, and political decisions.

Practitioners should be aware of the evolving landscape of obesity treatment options.